Phibro Animal Health Corp (PAHC) Stock Price & Analysis
Phibro Animal Health Corp (PAHC) fell 0.01% to USD 34.04 as of July 26, 2026 at 17:32 UTC, according to Nexqual real-time market data.
PAHC last closed at USD 34.04; the session ranged USD 33.68–34.75 on volume of 137,275 shares. Market capitalization is $1.38B, with a 52-week range of USD 25.58–60.08 (NGM). Source: Nexqual, July 26, 2026 at 17:32 UTC.
Key Statistics (as of July 26, 2026 at 17:32 UTC)
| Price | USD 34.04 |
|---|---|
| Change | ▼ 0.01% (down) |
| Previous Close | USD 34.04 |
| Open | USD 34.21 |
| Day Range | USD 33.68 – 34.75 |
| 52-Week Range | USD 25.58 – 60.08 |
| Volume | 137,275 shares |
| Market Cap | $1.38B |
| Exchange | NGM |
Technical Analysis (PAHC)
Nexqual's technical model rates PAHC "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 26, 2026 at 17:32 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.64 (neutral) |
| vs SMA50 | Above (USD 32.6) |
| MACD | 0.1 (positive) |
Analyst Ratings (PAHC)
Wall Street analysts rate PAHC "None" based on 5 analysts, with a mean price target of USD 45.6 (range USD 38–58), per Nexqual as of July 26, 2026 at 17:32 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 45.6 |
| High Target | USD 58 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 1 / 3 / 1 |
Earnings (PAHC)
| Next Earnings Date | 2026-08-26 |
|---|---|
| EPS Estimate | USD 0.73 |
| Revenue Estimate | $378.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.76 vs est 0.71 ▲ beat |
| 2025-12-31 | USD 0.87 vs est 0.67 ▲ beat |
| 2025-09-30 | USD 0.73 vs est 0.6 ▲ beat |
| 2025-06-30 | USD 0.57 vs est 0.52 ▲ beat |
Source: Nexqual, July 26, 2026 at 17:32 UTC.
Financials & Fundamentals (PAHC)
| Total Revenue | $1.50B |
|---|---|
| Revenue Growth (YoY) | +10.30% |
| Gross Margin | +32.57% |
| Operating Margin | +12.56% |
| Profit Margin | +6.35% |
| ROE | +30.34% |
| Debt / Equity | 217.97 |
| Current Ratio | 3.17 |
| Total Cash | $78.14M |
| Total Debt | $788.68M |
| Free Cash Flow | $-17.68M |
Source: Nexqual, July 26, 2026 at 17:32 UTC.
Financial Health Score (PAHC)
Nexqual rates Phibro Animal Health Corp's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 17:32 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 13% |
| Balance Sheet | Weak — $78M cash vs $789M debt |
| Cash Flow | Weak — FCF negative: -$18M, burning cash |
| Efficiency | Strong — ROE 30%, ROA 8.4% |
Ownership (PAHC)
| Insider Ownership | +0.85% |
|---|---|
| Institutional Ownership | +99.28% |
| Shares Outstanding | 21.07M |
| Float | 20.87M |
| Short % of Float | +6.88% |
Source: Nexqual, July 26, 2026 at 17:32 UTC.
Leadership (PAHC)
Phibro Animal Health Corp is led by Daniel M. Bendheim (age 53), CEO, President & Director, per Nexqual as of July 26, 2026 at 17:32 UTC.
| CEO, President & Director | Daniel M. Bendheim (age 53) |
|---|---|
| Executive Chairman | Jack Clifford Bendheim (age 78) |
| Chief Financial Officer | Glenn C. David (age 53) |
| Chief Operating Officer | Larry L. Miller (age 61) |
| Executive Vice President of Global Technology & People and Director | Jonathan Bendheim (age 48) |
Major Backers & Investors (PAHC)
Notable institutional backers of Phibro Animal Health Corp include FMR, LLC, Fidelity, Acadian Asset Management. LLC, according to Nexqual as of July 26, 2026 at 17:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 10.31% |
| Fidelity | 5.48% |
| Acadian Asset Management. LLC | 2.93% |
| Renaissance Technologies | 2.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.74% |
| Vanguard Group | 10.68% |
| State Street | 4.51% |
| Geode Capital | 2.87% |
| Dimensional Fund Advisors | 2.41% |
| Nuveen | 2.16% |
Source: Nexqual, July 26, 2026 at 17:32 UTC.
From Phibro Animal Health Corp's Latest SEC 10-K Filing (filed 2025-08-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
- It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
- The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
- It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VREX | Varex Imaging Corporation | USD 10.92 | ▲ 2.44% |
| OFIX | Orthofix Medical Inc. | USD 11.25 | ▲ 2.09% |
| JRVR | James River Group Holdings, Inc | USD 4.71 | ▲ 3.97% |
| LMAT | LeMaitre Vascular, Inc. | USD 95.59 | ▼ 3.26% |
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 17:32 UTC. This page is informational and not investment advice.